

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



A2

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 43/04, A61K 31/70, C07H 17/00, C12N 15/00		A1	(11) International Publication Number: WO 95/12979 (43) International Publication Date: 18 May 1995 (18.05.95)
(21) International Application Number: PCT/US94/12912		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ).	
(22) International Filing Date: 8 November 1994 (08.11.94)			
(30) Priority Data: 08/149,098 8 November 1993 (08.11.93) US			
(71) Applicant: THE UNIVERSITY OF SOUTHERN CALIFORNIA [US/US]; 3716 South Hope Street #313, Los Angeles, CA 90007-4344 (US).		Published <i>With international search report.</i>	
(72) Inventors: KEDES, Laurence, H.; 2234 Chislehurst Drive, Los Angeles, CA 90027 (US). SARTORELLI, Vittorio; 1540 Laurel Street #4, Pasadena, CA 91030 (US). PRENTICE, Howard, M.; 6 Craigbarnet Road, Milngavie G62 7RA (GB). KLONER, Robert, A.; 4825 Placidia Avenue, Toluca Lake, CA 91602 (US).			
(74) Agent: SPITALS, John, P.; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012 (US).			

(54) Title: COMPOSITIONS AND METHODS FOR TRANSDUCTION OF CELLS

(57) Abstract

A method of transducing proliferating cells to a novel phenotype by administering to the cells an amount effective to transduce at least a portion of the target cells of a composition wherein the active agent is a nucleotide molecule including at least one sequence corresponding to a cell lineage commitment gene and compositions for use in the method are described. Conversion of non-myocytes (for example, fibroblasts in the ischemic heart) to the skeletal muscle phenotype is effected by injection of a vector expressing a muscle regulatory factor gene. Cellular conversion through exogenous MyoD expression demonstrates the potential of converting one type of cell (for example, the areas of fibrotic tissue within the ischemic heart wall) to another (e.g., a skeletal muscle phenotype). Such tragedies lead to the development of alternative therapeutic interventions in a variety of conditions, including those involving injured or traumatized tissue (e.g., muscle in ischemic heart disease).

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

COMPOSITIONS AND METHODS FOR TRANSDUCTION OF CELLS

Background of the Invention

5 The present invention relates generally to the fields of biotechnology and medicine. More particularly, the present invention is directed to compositions and methods useful in the transduction of cells for therapeutic purposes.

10 Considerable research is currently being directed to techniques for somatic gene therapy, in which a therapeutic gene encoding a therapeutic protein is delivered to cells, tissues or organs manifesting a disease. One therapeutic approach involves introduction of a suitable vector containing the gene *ex vivo* into autologous cells from the site at which the therapy is directed, followed by reimplantation of the cells. Alternatively, introduction of genetic material directly into mammalian cells may be effected *in vivo* through the use of, e.g., viral particles functioning in the ordinary course of infection; retroviruses have been 15 found to be especially useful as vectors for accomplishing gene insertion.

20 Several strategies have been developed to use skeletal muscle tissue to influence the performance of a failing heart. Skeletal muscle grafts with neuronal innervation have been used clinically as a means of strengthening the contractions of the ischemic heart. Such approaches are subject to the limitations imposed by 25 surgical intervention and post operative side effects.

One possible way to circumvent these problems would be to transplant skeletal muscle cells into the myocardium in the hopes that they might fuse and form functional fragments of contractile tissue. Experimental attempts to insert such myogenic cells recently has been attempted in animal models, leading to the 25 formation of a patch of well demarcated skeletal muscle surrounded by normal myocardium [Koh, G.Y. et al. (1993) *Am. J. Physiol.*, **264**, H1727-H1733].

30 Gene transfer into the normal myocardium has been achieved through direct DNA injection, resulting in high level and long term expression from cell type specific, hormone responsive and ubiquitously active promoters [Lin, H. et al. (1990) *Circ.*, **82**, 2217-2221; Kitsis, R. N., et al. (1991) *Proceedings Of The National Academy Of Sciences Of The United States Of America*, **88**, 4138-42;

Acsadi, G. et al. (1991) *New Biol.*, **3**, 71-81; von Harsdorf, R. et al. (1993) *Circulation Research*, **72**, 688-95]. It had not heretofore been determined, however, whether directly injected foreign genes are transcribed in ischemic myocardium.

5 It is an object of the present invention to provide compositions and methods useful for the therapeutic transduction of cells. In particular, it is an object of the present invention to provide compositions and methods which may be employed in the treatment of injured or diseased muscle.

Summary of the Invention

10 In accordance with the present invention, delivery of a nucleotide sequence corresponding to a cell lineage commitment gene is employed to transduce proliferating cells to a novel phenotype. For example, proliferating fibroblasts are transduced to a myogenic phenotype as a technique for remediation of muscle injury or trauma. In a particular embodiment of the invention, delivery of muscle 15 regulatory factor gene to the myocardium is employed in order to convert to a myogenic phenotype the cells that populate a myocardial scar following infarction. Upon conversion of the proliferating cardiac fibroblasts to skeletal muscle cells, they strengthen the weakened heart wall, effect the tissue remodeling that accompanies post-infarction processes, and potentially contribute to contraction. 20 The feasibility of this approach is demonstrated by direct introduction of a myogenic determination gene, MyoD1, into the scar tissue of an experimental model of myocardial infarction.

Detailed Description of the Invention

In accordance with the present invention, it has now been demonstrated both 25 *in vivo* and in cell culture that it is possible to convert non-myocytes, for example fibroblasts in the ischemic heart, to the skeletal muscle phenotype by injection of a vector expressing a muscle regulatory factor gene. These observations on cellular conversion through exogenous MyoD expression indicate the potential of 30 converting one type of cell (for example, the areas of fibrotic tissue within the ischemic heart wall) to another (e.g., skeletal muscle phenotype) by delivery to the target cells of at least one nucleotide sequence corresponding to a cell lineage

commitment gene. Such strategies lead to the development of alternative therapeutic interventions in a variety of conditions involving injured or traumatized tissue (e.g., muscle in ischemic heart disease).

The present invention calls for the introduction of at least one nucleotide sequence corresponding to or functionally equivalent to (as hereinafter defined) a mammalian gene which regulates cell lineage commitment into a suitable proliferating cell. One type of gene of particular interest for use in accordance with the present invention is the family of muscle regulatory factor genes. The muscle regulatory factor gene family includes, but is not limited to, the following genes: myogenin [Edmondson, D.G. & Olson, E.N. (1989) *Genes & Development*, 3, 628-640]; Myf-5 [Braun, T. et al. (1989) *EMBO Journal*, 8, 701-709]; MRF4 [Rhodes, S.J. & Konieczny, S.F. (1989) *Genes & Development*, 3, 2050-2061]; and MyoD1 [Weintraub, H. et al. (1991) *Science*, 251, 761-766; Davis, R.L. et al. (1987) *Cell*, 51, 987-1000].

MyoD1 has been shown to convert non-muscle cells to the skeletal muscle phenotype *in vitro* [Weintraub, H. et al. (1989) *Proc. Natl. Acad. Sci. USA*, 86, 5434-5438; Choi, J. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87, 7988-92]. Members of this family of genes act as transcription factors capable of transactivating muscle specific genes [Lassar, A.B. et al. (1989) *Cell*, 58, 823-831], and display cell cycle suppressive activities [Crescenzi M. et al. (1990) *Proc. Natl. Acad. Sci. USA*, 87, 8442-6; Sorrentino V. et al. (1990) *Nature*, 345, 813-5]. Conversion of chondroblasts, epithelial, nerve, fat and fibroblast cells has been demonstrated in cell culture to varying degrees [Weintraub et al. (1989), *supra*; Choi et al., *supra*]. When expression of exogenous MyoD in cardiocytes is forced during development in transgenic mice, there is an hypertrophic response and conversion to the skeletal muscle phenotype [Miner, J.H. et al. (1992) *Development*, 114, 853-860]. However, it had not heretofore been established whether such phenotypic changes could be induced by introduction of a muscle regulatory factor gene into adult tissues *in vivo*.

The reported sequence for a MyoD cDNA [Davis et al., *supra*] is as follows:

ACACCTCTGACAGGACAGGA
5 CACAGCCGGTGTGCATTCCAACCCACAGAACCTTGTCA
TGTACTGTTGGGTTCCGGAGTGGCAGAAAGTTAAGACG
ACTCTCACGGCTGGGTGAGGCTGGACCCAGGA
10 ACTAGA
CTTGACAGGCCCGACGGCTCTCTGCTCCTTGAGA
CAGCAGACGACTTCTATGATGATCCGTGTTGACTCA
CCAGACCTGCGCTTTTGAGGACCTGGACCCGCGCCT
GGTGCACGTGGGAGCCCTCCTGAAACCGGAGGAGCAC
GCACACTTCTACTGCGGTGCACCCAGGCCAGGCG
15 CTCGTGAGGATGAGCATGTGCGCGCCAGCGGGCA
CCACCAGGCAGGTCGCTGCTGCTGTGGCCTGCAAG
GCGTCAAGCGCAAGACCACCAACGCTGATGCCGCA
AGGCCGCCACCATGCGCGAGCGCCGCCCTGAGCAA
AGTGAATGAGGCCTCGAGACGCTCAAGCGCTGCACG
TCCAGCAACCGAACCAAGCGGCTACCCAAAGGTGGAGA
20 TCCTGCGCAACGCCATCCGCTACATCGAAGGTCTGCAG
GCTCTGCTGCGCGACCAGGACGCCGCCCTGGCG
CCGCTGCCTCTACGCACCTGGACCGCTGCCCTCAGG
CCGTGGCAGCGAGCACTACAGTGGCGACTCAGACCG
TCCAGCCCGCCTCAACTGCTCTGATGGCATGATGGA
25 TTACAGCGGCCCCCAAGCGGCCCCGGCGGCAGAAT
GGCTACGACACCGCCTACTACAGTGA
GGCGTGCAG
AGTCCAGGCCAGGGAAAGAGTGC
GGCTGTGTCGAGCCT
CGACTGCC
20 CGCTGTCCAGCATAGTGGAGCGCATCTCCACA
GACAGCCCGCTGCGCCTGCGCTGCTTGGCAGATG
CACCACCAAGAGTCGCCTCCGGTCCGCCAGAGGGGGC
ATCCCTAAGCGACACAGAACAGGGAACCCAGACCCCG
TCTCCCGACGCC
30 CCCCAATGCGATTATCAGGTGCTTGAGAGATCGACT
GCAGCAGCAGAGGGCGCACCACCGTAGGC
ACTCCTGGGG

ATGGTGCCCTGGTCTTACGCCAAAAGATGAAGCTTA
AATGACACTCTCCAACTGTCCTTCGAAGCCGTTCTTC
CAGAGGAAGGGAGAGCAGAAGTCTGTCCTAGATCCAG
CCCCAAAGAAAGGACATAGTCCTTTGTTGTTGTTGTTG
5 TAGTCCTCAGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTG
GCGAAGGCCACTTGCACTCTGGCTGCACCTCACTGGGCC
AGAGCTGATCCTTGAGTGGCCAGGCGCTTCCTTCCTC
ATAGCACAGGGTGAGCCTGCACACCTAACGCCCTGCC
TCCACATCCTTTGTTGTCACTTCTGGAGGCCCTCCTGG
10 CACCCACTTTCCCCACAGCTGCGGAGGCCACTCAGGTC
TCAGGTGTAACAGGTGTAACCATAACCCACTCTCCCCCTT
CCCGCGGTTCAAGGACCACTTATTTTATATAAGACTTT
TGTAATCTATCGTGTAAATAAGAGTTGCTTGGCCAGAGC
GGGAGCCCTTGGCTATATTATCTCCAGGCATGCTGT
15 GTAGTGCAACAAAAACTTGTATGTTATTCAAGCGG
GCGAGTCAGGTGTTGGAAATCC [SEQ ID NO:1].

It is further reported that the sense orientation encodes only one open reading frame that is greater than 100 residues and has a good initiation sequence consensus (GATATGG); this portion of the molecule is indicated in bold face.

20 The reported sequence for a myogenin cDNA [Edmondson et al., *supra*] is as follows:

GGTCNNNNCTACAGAGGCCGGGGCGGGCCAGCCATGG
TGCCCAGTGAATGCAACTCCCAGGGCCCTNNCTGCGG
GACGTTGGGGGCCAGTGGCAGGAACAAGCCTTGCAC
25 CTGATGGAGCTGTATGAGACATCCCCCTATTCTACCA
GGAGCCCCACTTCTATGATGGGAAAACACCTTCCTG
TCCACCTTCAGGGCTTCAGCCCCCGGGCTATGAGCG
GACTGAGCTCAGCTTAAGCCCGGAAGCCCGAGGGCC
CTGGAAGAAAAGGGACTGGGACCCCTGAGCATTGTC
30 CAGGCCAGTGCCTGCCGTGGCATGTAAGGTGTGAA
GAGGAAGTCTGTGTCGGTGGACCGGAGGAGGGCAGCC

ACACTGAGGGAGAAGCGCAGGCTCAAGAAAGTGAATG
 AGGCCTCGAGGCCCTGAAGAGGGAGCACCCCTGCTCAA
 CCCCAACCAGCGGCTGCCTAAAGTGGAGATCCTGCGC
 CATGCCATCCAGTACATTGAGCGCCTACAGGCCTGCT
 5 CAGCTCCCTCAACCAGGAGGAGCGCGATCTCCGCTAC
 AGAGGCGGGGCGGGCCCAGCCCATGGTGCCAGTGA
 ATGCAACTCCCACAGCGCCTCCTGCAGTCCGGAGTGG
 GGCAATGCACTGGAGTTGGTCCCAACCCAGGAGATC
 ATTTGCTCGGGCTGACCTACAGACGCCACAATCTG
 10 CACTCCCTACGTCCATCGTGGACAGCATCACGGTGG
 GGATATGTCTGTTGCCCTCCAGACGAAACCATGCCA
 ACTGAGATTGTCTGTCAGGCTGGGTGTGCATGTGAGC
 CCCCAAGTTGGTGTAAAAGCCATCACTCTGTAGCAG
 GGGGCTTTAAGTGGGCTGCTGATGTCCAGAAAACA
 15 GCCCTGGGCTGCCACAAGCCAGACTCCCCACTCCCCATT
 CACATAAGGCTAACACCCAGCCCAGGGAGGGATTAGC
 TGACTCCTAAAGCAGAGAGCATCCTCTGAGGAGAG
 AAAGATGCAGTCCAGAGAGGCCCTGTTAATGTCCCTC
 AGTGGGCAAACTCAGGAGCTTTTGTATCATAT
 20 ATGCCTCGAATTCCACCCCCCACCCCCAAAATGAAACCG
 TTTGAGAGACATGAGTGCCCTGACCTGGACAAGTGTGCA
 CATCTGTTAGTCTTCCTGAAGCCAGTGGCTGGCTG
 GGCCTGCCCTGAGTTGAGAGAGAAGGGGGAGGAGCTATC
 CGGTTCCAAGCCTCTGGGGCCAAGCATTGCAGTGG
 25 TCTTGGNNNNNTCCAGTGTGTTGTATTGTTATTGTT
 TTGTGTGTTGTTGAAAGCTGCCGTGCCAAGGTCTCC
 TGTGCTGATGATACCGGGAACAGGCAGGCCAGGGGGTGG
 GGGCTCTGGGTGACTTCTTGTAACTAAGCATTGTG
 TGGTTTGCCAATTTTCTTTGTAATTCTTGCTAA
 30 CTTATTGGATTCCCTTTAAAAATGAATAAAGACTG

GTTGCTATCAGAAAAAAAAAAAAAAAAAAAAAA

[SEQ ID NO:2].

Once again, the reported longest uninterrupted ORF is indicated in bold.

The following nucleotide sequence for MRF4 cDNA has been reported

5 [Rhodes & Konieczny, *supra*]:

AGTCATCACCCAGTTCAGATCAGTCAGAGGCCAAGGAG
GAGAACATGATGATGGACCTTTGAAACTGGCTCCTA
TTTCTTCTACTTAGATGGAGAAAATGTGACTCTTCAGC
CATTAGAAGTGGCAGAGGGCTCTCCTTGTACCCAGG
10 GAGTGATGGTACCCATCCCCTGCCAGGACCAAATGC
CCCAGGAAGCCGGGAGCGACAGCAGTGGAGAGGAACA
CGTTCTGGCTCCCCCAGGCCTCAGCCACCCACTGCC
CAGGTCACTGTCTGATCTGGGCTTGCAAGACTTGCAAG
AGAAAATCTGCCAACAGATCGTCGAAAGCAGCTA
15 CCCTGCGCAAAGGAGGAGGCTTAAGAAAATCAACGA
AGCCTTGAGGCCTTGAAGCGTAGAACTGTGGCCAAC
CCCAACCAGAGGCTGCCAAGGTGGAGATTCTGAGAA
GTGCCATCAACTACATTGAGCGTCTGCAGGACCTGCTG
CACCGGCTGGATCAGCAAGAGAAAATGCAGGAGCTGG
20 GGGTGGACCCCTACAGCTACAAACCAAGCAAGAAATT
CTTGAGGGTGCCTGGATTTCTGCACCTGCAGCCCGC
AGTGGCCAAGTGTTCGGATCATTCCAGGGCCTGGT
GATAACTGCTAAGGAAGGAGGAGCAAGCGTCATGCT
TCAGCCTCCAGCAGTCTCAGCGCCTTCTCCATCGT
25 GGACAGTATTCTCAGAGGAACGCAAACCTCCCCAGC
GTGGAGGAGGTGGAGAAGTAACACTCAGTCAGCATT
GGAACATTCTCGCTCAGCAGGAAGAGCCCCTTCCGCCT
AATCATTAGATTAGGGCTCACAGACCCAGAATTATGA
AAGGCAAGAGACTTAGTGTAAAAAAGAAACCTCTCCC
30 ACCTCAAGTAAAATCCTCGGCTGGGCTTTATTATA
ACTATTATTGTATCTGAACCGCTAGTGGCTAGCTAGA

ACCCTAATTTGTTTAGTTGGTTGGTTTATAACAT
 ATTAACCTTGCTATGATCACGTGACCCTTCCTGTCAGT
 TGCAAACGAAGTCATTCTGTCTAAATCAAAGTGGGAA
 CGTTAACCTAAGAGTATTAATGTACTTTGTAAATAG
 5 TCTTAGTACTTCGTTTATGTAACCTAAAGGACATAT
 TTTAAATGTGGAATTAAGCATTGTATATAAAATGTGTGAG
 AGTCTGATATTGTAATATTAAAATTAATACGTTCTAC
 ACGTAAAAAAAAAAAAAAAAAAAAA [SEQ ID
 NO:3].

10 The single major ORF is indicated in bold.
 A Myf-5 cDNA sequence has been reported [Braun et al., *supra*] as
 follows:

CCTCTCGCTGCCGTCCAGGTGCACCGCCTGCCTCTCAGCA
 GGATGGACGTGATGGATGGCTGCCAGTTCTCACCTTCT
 15 GAGTACTTCTACGACGGCTCCTGCATACCGTCCCCGA
 GGGTGAATTGGGGACGAGTTGTGCCGCCAGTGGCT
 GCCTCGGAGCGCACAAAGCAGAGCTGCAGGGCTCAG
 ATGAGGACGAGCACGTGCGAGCGCCTACCGGCCACCA
 CCAGGCTGGTCACTGCCTCATGTGGCCTGCAAAGCC
 20 TGCAAGAGGAAGTCCACCAACCATTGGATGGCGGAAGG
 CAGCCACTATGCGCGAGCGGAGGCCCTGAAGAAGGT
 CAACCAGGCTTCGAAACCTCAAGAGGTGTACACGA
 CCAACCCCAACCAGAGGCTGCCAAGGTGGAGATCCT
 CAGGAATGCCATCCGCTACATCGAGAGCCTGCAGGAG
 25 TTGCTGAGAGAGCAGGTGGAGAACTACTATAGCCTGC
 CGGGACAGAGCTGCTGGAGCCCACCAGCCCCACCTC
 CAACTGCTCTGATGGCATGCCGAATGTAACAGTCCTG
 TCTGGTCCAGAAAGAGCAGTACTTTGACAGCATCTAC
 TGTCTGATGTCAAATGTATGCCACAGATAAAAAA
 30 CTCCCTATCCAGCTGGATTGCTTATCCAACATAGTGG
 ACCGGATCACCTCCTCAGAGCAACCTGGTTGCCTCTC

CAGGATCTGGCTCTCTCTCCAGTTGCCAGCACCGA
TTCACAGCCTCGAACTCCAGGGGCTTAGTTCCAGGC
TTATCTATCATGTGCTATGAACATAATTCTGGTCTATAT
GAATTCTCCAGGAGGGCCTAATACACAGGACGAAGAAG
5 GCTTCAAAAAGTCCAAACCAAGACAACATGTACATAAA
GATTCTTTCAAGTTGAAATTGTAAGATTACCTTGCC
ACTTTATAAGAAAGTGTATTTAACTAAAAAGTCATCATTG
CAAATAATACTTCTTCTTATTATTCTTGCTTAGAT
ATTAATAACATAGTTCCAGTAATACTATTCTGATAGGGGG
10 CCATTGATTGAGGGTAGCTGTTCGAATGCTTAACCTATA
TATACATATATATATTATAAAATTGCTCATCAAAATG
TCTCTGGTGTAGAGCTTATTCTTAAACATTA
AAACAGCTGAGAATCAGTTAAATGGAATTAAATATATT
TAACATTCTTCTTTCTTAATCCTTAGTTATATTGTAT
15 TAAATAAAATATAACTGCCTAATGTATATATTGAT
CTTTCTTGTAAAGAAATGTATCTTAAATGTAAGCACAA
AATAGTACTTGTGGATCATTTCAAGATATAAGAAATT
GGAAATTCCACCATAAATAAAATTCTTACTACAAGAAAAA
[SEQ ID NO:4].

20 The single ORF in both orientations as reported is indicated in bold.

In the retroviral mediated gene therapy experiments in ischemic heart models reported herein, proliferating fibroblasts represent the most likely target cell. This is based on a) the propensity of retroviral transduction for proliferating cells and b) the observation that following ischemic injury in adult myocardium the 25 cardiomyocytes do not proliferate.

The strategy of using at least one muscle regulatory factor gene to convert cells in a cardiac scar *in vivo* is useful in strengthening the contractions of the injured heart and preventing the deleterious consequences of myocardial remodeling following infarction. Thus, the present invention is particularly useful in the 30 treatment of heart muscle that is weak or functioning poorly. A prime situation for use of the inventive protocol is the treatment of ischemic heart tissue resulting from

coronary artery disease or coronary infarction. Other pathologic abnormalities resulting in muscle which is weak or functioning poorly (such as cardiomyopathy, hypertensive heart disease or long-standing valvular disease) may also be ameliorated in accordance with the inventive method.

5 Moreover, the ability to deliver genes such as MyoD to organs and tissues by various delivery vectors could have more widespread use than the heart model described in detail herein. For example, the present invention has a clear utility in the conversion of non-muscle cells to skeletal muscle phenotype in repair of other injured or ischemic muscles, including but not limited to muscles of the eye, 10 hand and foot. MyoD was the first identified mammalian gene that appears to regulate cell lineage commitment. It is likely that other such genes exist that are master switches for other tissue types (such as nerves, skin, bone and cartilage). As such genes are characterized, they are also suitable for use in accordance with the present invention for therapeutic conversion.

15 The present invention involves the administration of therapeutic compositions useful in the transduction of proliferating cells to a novel phenotype, as well as in delivering a therapeutic nucleotide sequence corresponding to a cell lineage commitment gene to those cells. Exemplary nucleotide sequences corresponding to cell lineage commitment genes for use in accordance with the 20 present invention include members of the muscle regulatory factor gene family or functional equivalents thereof. By a "functional equivalent" of a muscle regulatory factor gene is intended a nucleotide sequence or portion thereof encoding a peptide corresponding to a product of a member of the muscle regulatory factor gene family or a portion of such a peptide sufficient to achieve the desired transduction 25 of proliferating cells to a myogenic phenotype. Although various reported cDNA sequences for members of the muscle regulatory factor gene family are disclosed herein, also contemplated as clearly within the scope of the present invention are variant forms of the heretofore-identified muscle regulatory factor genes and functional equivalents thereof, including sequences containing mutations and 30 deletions, which are competent to encode a peptide which achieves the desired cell transduction. In particular, those portions of the reported cDNA sequences

identified as encoding the corresponding muscle regulatory factor, degenerate sequences encoding these factors, and sequences encoding peptides which are functionally equivalent to these factors in transducing target cells would be immediately recognized by those skilled in the art as equivalents and thus well 5 within the scope of the present invention. Similar considerations apply with respect to other cell lineage commitment genes and nucleotide sequences corresponding to cell lineage commitment genes.

In addition, preferred nucleotide sequences include an active constitutive or inducible promoter sequence as are well known in the art. Conventional 10 engineered vector constructs, such as plasmid and bacteriophage (phage) vectors, containing suitable promoter sequences are useful in accordance with the present invention. These and other DNA sequences which are able to replicate in a host cell may be employed in accordance with the present invention as cloning vehicles in a manner well known in the art. The therapeutic nucleotide sequence of the 15 present invention may suitably comprise a DNA construct capable of generating therapeutic nucleotide molecules in high copy numbers in the target cells, as described in published PCT application WO 92/06693, the entire disclosure of which is hereby incorporated by reference. Further, a wide variety of known retroviral vectors may also be employed in accordance with the present invention. 20 Transduction with viral vectors has been valuable as a tool for obtaining high level gene expression in a high proportion of cells within a target area [Nabel, E.G. et al. (1989) *Science*, 244, 1342-4; Nabel, E.G. et al. (1991) *Journal Of The American College Of Cardiology*, 17 189B-194B]. Retroviral vectors preferentially infect dividing cells and for this reason are not useful to transduce a terminally 25 differentiated cell type, such as cardiomyocytes. They would, however, be expected to transduce proliferating cardiac fibroblasts *in vivo* following ischemic injury.

Recent DNA transfer techniques employing uptake of recombinant adenovirus by normal myocardium [Stratford-Perricaudet, L.D. et al. (1992) 30 *Journal of Clinical Investigation*, 90, 626-30] may also be particularly applicable to myocytes following ischemia and reperfusion in accordance with the present

invention. Recombination of such vectors is rare; there are no known associations of human malignancies with adenoviral infections despite common human infection with adenoviruses; the genome may be manipulated to accommodate foreign genes of a fairly substantial size (up to about 7.5 kb in length); live adenovirus has been 5 safely used as a human vaccine; and host proliferation is not required for expression of adenoviral proteins.

In various embodiments of the present invention, therapeutic compositions useful for practicing the therapeutic methods described herein are contemplated. Therapeutic compositions of the present invention may contain a physiologically acceptable carrier together with one or more therapeutic nucleotide sequences as described herein, dissolved or dispersed in the carrier, as the active ingredient. In 10 preferred embodiments of the invention, the composition is not immunogenic or otherwise able to cause undesirable side effects when administered to a mammal or human patient for therapeutic purposes.

15 As used herein, the term "physiologically acceptable" as applied to compositions, carriers, diluents and reagents, represents that the materials are capable of administration to or upon a mammal, including a human patient, without the production of undesirable physiological effects, including but not limited to nausea, dizziness, gastric upset and the like.

20 The preparation of a pharmacological composition which contains active ingredients dissolved or dispersed therein is well understood in the art. Typically, such compositions are prepared for purposes of injection as liquid solutions or suspensions; however, solid forms suitable for solution or suspension in liquid prior to use may also be prepared.

25 Physiologically acceptable carriers are well known in the art. Exemplary liquid carriers for use in accordance with the present invention are sterile aqueous solutions which contain no materials other than the active ingredient and water, or may contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both (i.e., phosphate-buffered saline). Suitable aqueous 30 carriers may further comprise more than one buffer salt, as well as other salts (such as sodium and potassium chlorides) and/or other solutes.

The active ingredient may further be mixed in amounts suitable for use in the therapeutic methods described herein with one or more excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients include dextrose, glycerol, ethanol and the like, and combinations of one or more thereof with vegetable oils, propylene glycol, polyethylene glycol, benzyl alcohol and the like to provide a suitable injectable composition. In addition, if desired, the composition can contain wetting or emulsifying agents, isotonic agents, pH buffering agents, dissolution promoting agents, stabilizers, antiseptic agents and other typical auxiliary additives employed in the formulation of pharmaceutical preparations. In another variation, the therapeutic nucleotide sequences of the present invention may be incorporated into liposomal vesicles [see, e.g., U.S. Patent 5,104,661; U.S. Patent 5,013,556; and published PCT application WO 92/06192, the entire disclosures of which are hereby incorporated by reference].

A therapeutic composition for use in accordance with the present invention typically contains an amount of the therapeutic nucleotide sequence as described herein sufficient to deliver a therapeutically effective amount to the target tissue. Following the protocols described herein, at least about 10% of the target cells in an infarcted area are transduced upon administration of a therapeutic composition in accordance with the present invention, and preferably about 20% to about 30% are affected. It is anticipated that with the use of more powerful vectors, transduction of at least 50% of the target cells can be achieved. For purposes of the present invention, it is contemplated transduction of at least a portion of the target cells corresponding to about 10% thereof is sufficient to achieve a desired therapeutic effect. Typically, the compositions comprise at least about 0.1 weight percent to about 90 weight percent of therapeutic nucleotide sequence per weight of total therapeutic composition.

The therapeutic nucleotide compositions comprising synthetic oligonucleotide sequences in accordance with the present invention may be prepared in a manner known per se to those skilled in the art by suitable method, including but not limited to the phosphotriester and phosphodiester methods, as

described in, e.g., Narang et al., *Meth. Enzymol.* 68:90 (1979), Brown et al., *Meth. Enzymol.* 68:109 (1979) and U.S. Patent 4,356,270.

The method of the present invention generally comprises contacting specific cells with a therapeutically effective amount of a pharmaceutically acceptable composition comprising a therapeutic nucleotide sequence of this invention. This contact may suitably be effected by a direct injection of the compositions into tissues or organs comprising the target cells. Alternatively, for treatment of ischemic tissue intracoronary administration may be effected via a catheter. Finally, intravenous administration of suitable compositions may be employed.

Whereas skeletal muscle grafted onto heart by cardiomyoplasty is innervated [Hooper, T.L. et al. (1993) *Surgery Annual*, 1, 157-73] non-myocytes converted to skeletal muscle with MyoD may require electrical stimulation if they are to contract. Thus, to effectively repair damage cardiac tissue the conduction system of the newly-created skeletal muscle must be coupled to that of the healthy cardiac tissue. The electrical currents present in the cardiac tissue could be sufficient to induce coupling to the adjacent skeletal muscle tissue. Alternatively, exogenous transfer of cardiac gap junction protein [Beyer, E.C. et al. (1987) *Journal of Cell Biology*, 105, 2621-9; Fishman, G. I. et al. (1990) *Journal of Cell Biology*, 111, 589-98; Beyer, E.C. et al. (1990) *Journal of Membrane Biology*, 116, 187-94] by gene transfer would permit coupling between these different muscle cell types. To stimulate sympathetic innervation, exogenous expression of the gene for nerve growth factor (NGF) within the converted myotubes may lead to creation of a conduction system within the skeletal muscle tissue.

A further consideration in attempts to ensure the conversion of scar to contractile muscle within the heart is the lack of vascularization of the infarcted region. To solve this problem exogenous expression of angiogenic factors such as acidic and basic FGF by gene transfer [Barr, E. et al. (1991) *Circulation*, 84 (Suppl II), II-420] could lead to neovascularization within the ischemic area. To obtain sufficient levels of these foreign proteins within newly formed skeletal muscle careful attention must be paid to the use of appropriate promoter/enhancer systems that will ensure high level and long term gene expression. For this

purpose striated muscle specific promoters whose specificity was validated *in vivo* would be suitable choices. Alternatively, if these foreign genes were introduced into unconverted cardiac fibroblasts a strong promoter would be appropriate to give high level gene expression.

5 The invention may be better understood with reference to the accompanying examples, which are intended for purposes of illustration only and should not be construed as in any sense limiting the scope of the present invention as defined in the claims appended hereto.

Examples

10 The plasmid RSV (Rous Sarcoma Virus)-luciferase containing the luciferase gene under the control of the Rous Sarcoma Virus promoter is described in R. Kitsis et al., *supra*. Amphitrophic retroviruses containing the MyoD coding sequence were obtained as a supernatant from PA317 cells. First, 2 ml of retroviral supernatant derived from LMDSN infected ψ cells was used to transduce 15 PA317 cells at a density of 5×10^5 cells/100 mm dish. Infection was conducted for 3 hours after which the culture medium was changed. 24 hours later cells were split 1:400 for selection in G418 containing medium (1.5 mg/ml) and cultured until antibiotic resistant colonies were visible. One such colony was used as a source of MyoD encoding amphotrophic retrovirus.

20 To test whether functional MyoD protein was expressed by the amphotrophic retrovirus, 2 ml of retroviral supernatant was used to infect 10T1/2 cells at 5×10^5 cells/ 100 mm dish. Cells were infected for 3 hours and transferred to fresh medium. 24 hours later cells were split 1:20 for selection in G418 containing medium. After 3 weeks in culture approximately 100 25 colonies/dish were formed. These colonies contained cells that differentiated into an extensive array of multinucleated myotubes which confirmed that functional MyoD was expressed by the amphotrophic retrovirus.

30 β -galactosidase encoding retrovirus was obtained from a PA317 clone transduced with LNPOZ. The viral titer of LNPOZ was 5×10^5 colony forming units per ml.

For preparation of retroviral supernatants (LMDSN or LNPOZ) transduced PA317 cells were grown to a density of 5×10^5 cells/100 mm dish and cultured in the absence of G418 for 24 hours after which supernatants were moved and stored at -80°C. The LMDSN vector is described in Weintraub et al. (1989), *supra*.

5 Tissue was homogenized with a Polytron (Kinematic, Switzerland) for 45 sec in 1 ml of ice cold homogenization buffer [Brasier, A.R. et al. (1989) *BioTech.*, 7, 1116-1122]. For measurements of luciferase activity samples were assayed for peak light production at 10 sec with a Monolight model 2001 10 luminometer (Analytical Luminescence Laboratory). 100 μ l of each homogenate was combined with 350 ml of Buffer B and 100 μ l of the buffer containing D-luciferin.

To assay for β -galactosidase, 3 mm sections of tissue were fixed in 4% paraformaldehyde in phosphate buffered saline (PBS) for 10 min at room temperature and incubated for 2 hours at 37°C in 1 mM 5-bromo-4-chloro-3-indolyl- β -D-galactoside (X-gal), 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl₂. Samples were then embedded in OCT compound and 15 10 μ frozen sections were cut and counterstained with nuclear fast red.

Photomicroscopy was performed using Scotchrome 1000 film and a Zeiss microscope. Immunostaining of frozen tissue sections for skeletal specific MHC 20 performed using monoclonal antibody MY-32 (Sigma) at 1:400 dilution and anti-chicken α -actinin antiserum (Sigma) at 1:500 dilution. Staining was visualized using fluorescein conjugated goat anti-mouse immunoglobulin G (skeletal MHC) and rhodamine conjugated goat anti-rabbit immunoglobulin G (α -actinin).

For determination of collagen content in infarcted areas tissue was fixed in 25 formalin and embedded in paraffin. Sections were cut and stained with hematoxylin and eosin and picrosirius red.

Example 1

Cell Culture

Neonatal rat cardiac fibroblasts were isolated according to the literature 30 procedure [Simpson, P. et al. (1982) *Cir. Res.*, 50, 101-116]. Heart tissue was finely minced and subjected to gentle trypsinization and mechanical disruption for

4-5 hours. Disassociated cells were plated for 30-60 minutes on 100 mm tissue culture dishes, after which the culture medium containing the cardiomyocytes was removed. Adherent cardiac fibroblasts were then expanded in culture for retroviral transduction. Cardiac fibroblasts were plated in 60 mm dishes with 5×10^5 cells/dish and polybrene was added at 8 $\mu\text{g}/\text{ml}$. Cells were infected with 100 μl of retroviral supernatant for 2 days. The cells were detached by trypsinization and seeded at densities ranging from 300 to 60,000 cells per plate. The cells were grown in the presence of G418 (800 $\mu\text{g}/\text{ml}$) and the medium changed every 3-4 days. After 12 days in culture G418 resistant colonies were isolated.

10 After transduction of the primary neonatal rat cardiac fibroblasts with either LMDSN carrying the MyoD and neomycin resistance genes or LMDSN carrying only the neomycin resistance gene, cells resistant to G418 were compared. The morphology of the LMDSN transduced cells was distinctive compared to that of cells transduced with vector alone. The former had been converted to a markedly 15 extended shape and formed elongated multinucleated cells compared to the rounded fibroblast morphology retained by the control cells. Only the LMDSN transduced cells reacted positively with an antibody specific to the skeletal muscle-specific isoform of myosin heavy chain. Thus, primary cardiac fibroblasts can be converted to the skeletal muscle phenotype by overexpression of MyoD.

Example 2Rat Model of Myocardial Ischemia and Reperfusion

Female Sprague Dawley rats were anesthetized with 0.1 ml/100 g (body weight) of ketamine (50mg/ml) and xylazine (10mg/ml) injected intra-peritoneally and the chests were surgically opened to expose the beating heart. The coronary artery was occluded as described [Li, Y. et al. (1992) *Cardiovascular Research*, 26, 226-31] for 15 (n=12) or 60 minutes (n=6) followed by reperfusion. DNA injections (1-3 per rat) were performed 15 minutes later, after which the chest was closed. The DNA solution contained 50 μ g of pRSVLuc and 1% (vol/vol) Evans blue dye. 11 rats served as sham, non ischemic controls for the 60 minute group. Animals were sacrificed 7 days after surgery and hearts were removed for analysis of luciferase activity.

Whereas genes delivered by direct heart injection into normal hearts enter myocardial cells and are expressed, it had not been determined whether ischemic or otherwise injured myocardium would also be capable of accepting and expressing exogenously delivered DNA. Accordingly a short (15 minute) and a long (60 minute) interval of myocardial ischemia followed by reperfusion were used in order to engender different degrees of injury to the myocardium, which was then followed by direct injection of reporter genes. Hearts were excised 7 days after the injection to determine whether the injected gene was expressed. The results are presented in Table 1. Since the number of DNA injections varied from animal to animal the absolute values of luciferase activity observed in the injected hearts can be taken only as an indication of whether ischemic myocardium can process and robustly express exogenous genes and cannot be used to compare between sham and ischemic groups.

High level RSV-luciferase reporter gene activity was observed after delivery of exogenous DNA to the ischemic area of occluded hearts. The peak light production from these mildly ischemic heart samples did not differ from the levels obtained in non ischemic control animals. Significant levels of luciferase expression above 100 light units (measured over 10 seconds) were obtained with ten of 12 rats in the ischemia/reperfusion group and nine of 11 rats in the non-

ischemic control group. Rats that failed to express likely did so because of faulty injection. One hour occlusion with 7 days of reperfusion also resulted in a high level of gene expression. There was a trend (not statistically valid) toward greater expression in this ischemic/reperfusion group compared to the non-ischemic group.

5 Five of 6 rats in the non-ischemic control group and all 6 rats in the ischemic group expressed significant amounts of luciferase activity.

Example 3

Production of Myocardial Infarction in Dogs

Mongrel dogs were anesthetized with sodium pentobarbital (35 mg/kg),
10 intubated, and ventilated. Myocardial infarcts were created percutaneously by embolizing alpha helix thrombotic coils (Target Therapeutics) into the left anterior descending coronary artery, under fluoroscopic guidance. Angiography was repeated at approximately 20-40 minutes to confirm coronary occlusion.

Six to 11 days after coronary occlusion the dogs were anesthetized,
15 intubated, and ventilated. The chest was shaved, prepped with betadine and the animal draped. Using sterile procedure, a thoracotomy was performed in the fifth intercostal space. The pericardium was incised, exposing the anterior surface of the left ventricle. This allowed visualization of the infarct as pale-yellow, non contracting tissue in the antero-apical wall of the left ventricle. Retrovirus was
20 injected directly into the wall of the heart.

Retroviral supernatants of LNPOZ and LMDSN were mixed in equal volumes and injected through a 27 gauge needle into the visible infarct within an area of 1 cm². The location of the injections was marked with a suture. Three injections, each of 0.3 ml, were made per infarct. For injection of LNPOZ, viral
25 supernatant was diluted 1:1 with growth medium and 0.3 ml of solution was injected at 3 sites within the infarcted area. After injection the chest was closed, air was evacuated from the chest, and the dogs were allowed to recover for 7-12 days. At 7-12 days the dogs were euthanized and hearts excised for analysis. Sections were obtained for immunostaining and histology.

30 This example was an attempt to convert to a skeletal muscle phenotype the cells present in a scar forming in the living animal after a myocardial infarction.

WO 95/12979

20

The density of dividing cells in a myocardial scar is at its peak 5-14 days after infarction and retroviruses preferentially transduce only proliferating cells. Accordingly, this time period was chosen to inject MyoD expressing retroviruses into a grossly infarcted segment of myocardium. Six dogs entered the study on 5 MyoD gene transfer. As presented in Table 2, five of six dogs had developed gross myocardial infarctions when observed following thoracotomy at 6-11 days post coronary artery occlusion. Four dogs were injected with both LNPOZ and LMDSN. Two dogs (one of which was the dog that did not develop infarction) were injected with LNPOZ only.

10 To establish whether retroviral uptake was possible in the infarcted area and to localize precisely the injection site, the LNPOZ retrovirus carrying the β -galactosidase gene was injected. Seven to 12 days after injection of retrovirus into ischemic dog heart the area of gene transfer was confirmed by Xgal staining. 3 out of 4 dogs injected with both LNPOZ and LMDSN stained positively for β -galactosidase (Table 2). The one dog with an infarct that was injected with LNPOZ alone served as a control and also stained positive for β -galactosidase.

15 To determine whether expression of the MyoD gene in these injected animals resulted in conversion of cells to the skeletal muscle phenotype, frozen section were stained with an antibody specific to skeletal fast myosin heavy chain (alpha-MHC). Only in sections from β -galactosidase positive tissue of the 3 dogs 20 injected with both LMDSN and LNPOZ were found multiple small clusters of cells that stained positive for skeletal fast MHC. These cells co-stained positive for the muscle marker alpha-actinin. No such cells were found in surrounding uninfarcted myocardium, in normal myocardium or in the cardiac scar of the animal injected with LNPOZ alone. Skeletal muscle from the diaphragm of one dog with the 25 specific anti-alpha-MHC monoclonal antibody was also stained. As expected, the myofibers stained positively. Similar sections of normal myocardium do not react with this antibody.

30 These data indicate that a percentage of cells in the infarcted area injected with a MyoD expressing retrovirus underwent conversion to the skeletal muscle phenotype. The lower number of cells converted may be due to the fact that the

retrovirus was of a low titer or perhaps the period of time after gene transfer was not optimal for cellular conversion. It is likely that the cell type converted by MyoD was not the cardiomyocyte because such a severe infarct leads to extensive loss of cardiomyocyte viability. The fact that retroviruses preferentially infect 5 dividing cells also points to non-myocytes as the target cells for conversion.

Tissue obtained from the infarcted areas of all dog hearts revealed loss of myocytes with infiltration of fibroblasts and mononuclear cells into the region. Picosirius red staining revealed bright red areas of collagen deposition which were easily distinguished from surrounding viable myocytes at the edge of the infarct 10 which stained yellow. No definite skeletal muscle myotubes were identified.

The high levels of gene expression obtained from DNA directly injected following 15 minutes of occlusion and reperfusion did not differ from levels obtained with sham operated rats. It is notable that expression of RSV-luciferase was increased following ischemia resulting from 1 hour occlusion. This 15 observation suggests that ischemic injury may increase DNA uptake into cardiocytes, perhaps through alterations in cellular permeability. Such changes in cellular permeability following coronary artery occlusion have been reported [Harper, I.S. et al. (1989) *Basic Research In Cardiology*, **84**, 208-26]. Thus, foreign genes can be taken up by direct injection into ischemic/reperfused 20 myocardium and transcribed by a strong promotor.

The lack of any skeletal MHC positive multinucleated myotubes in the injected tissue may have been due to the relatively low number of cells that were converted to the skeletal phenotype. It is likely, however, that with the use of retroviruses of a higher titer or of viral vectors such as adenovirus, a higher 25 percentage of cardiac fibroblasts could be converted to the skeletal muscle phenotype *in vivo* and myotubes might be formed. It is also possible that the experiments underestimated the fraction of cells that took up the retrovirus and expressed MyoD. Expression of MyoD soon after uptake of the retrovirus might well lead to a rapid withdrawal from the cell cycle, allowing uninfected 30 neighboring cells to selectively proliferate and greatly outnumber the transduced, MHC positive cells at the time of sampling 7-10 days after infection.

WO 95/12979

22

From the foregoing description, one skilled in the art can readily ascertain the essential characteristics of the invention and, without departing from the spirit and scope thereof, can adapt the invention to various usages and conditions. Changes in form and substitution of equivalents are contemplated as circumstances 5 may suggest or render expedient, and although specific terms have been employed herein, they are intended in a descriptive sense and not for purposes of limitation.

Table I
Effect of Ischemia/Reperfusion
on Recombinant Protein Expression

15 Min	Non Ischemic		Ischemic	
	Animal*	Light Units	Animal	Light Units
1	28522		12	3355
2	4148		13	32432
3	628		14	2024
4	28361		15	3089
5	575		16	418
6	6928		17	3538
7	7666		18	29640
8	938		19	813
9	154		20	535
			21	236
<hr/> 60 Minutes <hr/>				
Animal**				
	24	8597	30	248
25	279		31	7183
26	7700		32	43229
27	4062		33	6080
28	11104		34	22287
			35	524

*Two additional animals in each group had no detectable luciferase activity

**One additional animal in the Non Ischemic group had no detectable luciferase activity.

TABLE 2

Dog No.	Retrovirus Injection		Injection Protocol (interval in days)		Gross Infarct at time of injection	β-gal	MHC	Actinin	COMMENT
	LNPOZ	LMDSN	Injection	Euthanized					
2952	+	+	10	12	+	-	N.D.	N.D.	Failed injection. No DNA uptake
2953	+	+	10	12	+	+	+	+	
2959	+	+	6	7	+	+	+	+	
3038	+	-	6	9	-	-	N.D.	N.D.	No infarct. No DNA uptake
3041	+	+	6	8	+	+	+	+	
3043	+	-	11	7	+	+	-	-	

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: UNIVERSITY OF SOUTHERN CALIFORNIA

5 (ii) TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
TRANSDUCTION OF CELLS

(iii) NUMBER OF SEQUENCES: 4

10 (iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: c/o Robbins, Berliner & Carson
(B) STREET: 201 North Figueroa Street, Fifth Floor
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: U.S.A.
(F) ZIP: 90012

15 (v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25

20 (vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

25 (viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Spitals, John P.
(B) REGISTRATION NUMBER: 29,215
(C) REFERENCE/DOCKET NUMBER: 1920-341

(ix) TELECOMMUNICATION INFORMATION:
30 (A) TELEPHONE: (213) 977-1001
(B) TELEFAX: (213) 977-1003

(2) INFORMATION FOR SEQ ID NO:1:

35 (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1785 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

WO 95/12979

26

ACACCTCTGA CAGGACAGGA CAGGGAGGAG GGGTAGAGGA CAGCCGGTGT	60
CCACAGAACCTTGTCTTG TACTGTTGGG GTTCCGGAGT GGCAGAAAGT TAAGACGACT	120
CTCACGGCTT GGGTTGAGGC TGGACCCAGG AACTGGGATA TGGAGCTCT ATCGCCGCCA	180
CTCCGGGACA TAGACTTGAC AGGCCCCGAC GGCTCTCTCT GCTCCTTGA GACAGCAGAC	240
5 GACTTCTATG ATGATCCGTG TTTGACTCA CCAGACCTGC GCTTTTTGA GGACCTGGAC	300
CCGGCGCTGG TGCACCGTGG AGCCCTCTG AAACCGGAGG AGCACCGACA CTTCCTCTACT	360
GCGGTGCAACCAGGCCAGG CGCTCGTGAG GATGAGCATG TGGCGCGCC CAGCGGGCAC	420
CACCAAGGGCGG GTCGCTGCTT GCTGTTGGCC TGCAAGGGGT GCAAGGGCAA GACCACCAAC	480
GCTGATCGCC GCAAGGCCGC CACCATGCCG GAGCGCCGCC GCGTGTGAGAA AGTGAATGAG	540
10 GCCTTCGAGA CGCTCAAGCG CTGCACGTCC AGCAACCCGA ACCAGCGGCT ACCCAAGGTG	600
GAGATCTGC GCAACGCCAT CCGCTACATC GAAGGCTCTGC AGGCTCTGCT GCGCGACCAAG	660
GACGCCGCCGC CCCCTGGCGC CGCTGCCTTC TACGCACCTG GACCGCTGCC CCCAGGCCGT	720
GGCAGCGAGC ACTACAGTGG CGACTCAGAC GCGTCCAGCC CGCGCTCCAA CTGCTCTGAT	780
GGCATGATGG ATTACAGCGG CCCCCCAAGC GGCCCCCGGC GGCAGAATGG CTACGACACC	840
15 GCCTACTACA GTGAGGCCGT GCGCGAGTCC AGGCCAGGGAGA AGAGTGCAGC TGTGTCGAGC	900
CTCGACTGCC TGTCCAGCAT AGTGGAGCGC ATCTCCACAG ACAGCCCCGC TGCCCTGCC	960
CTGCTTTGG CAGATGCACC ACCAGAGTCG CCTCCGGGTC CGCCAGAGGG GGCATCCCTA	1020
AGCGACACAG AACAGGGAAC CCAGACCCCCG TCTCCCGACG CGCCCGCTCA GTGCTCTGCA	1080
GGCTCAAACC CCAATGCGAT TTATCAGGTG CTTTGAGAGA TCGACTGCAG CAGCAGAGGG	1140
20 CGCACCAACCG TAGGCACCTCC TGGGGATGGT GCCCCCTGTT CTTCACGCCA AAAAGATGAA	1200
GCTTAAATGA CACTCTTCCC AACTGTCTT TCGAAGCCGT TTTCCAGAG GGAAGGGAAAG	1260
AGCAGAAAGTC TGTCTCTAGAT CCAGCCCCAA AGAAAGGACA TAGTCCTTT TGTTGTTGTT	1320
GTGCTAGTCC TTCAGTTGTT TGTTGTTTT TTCATGCGGC TCACAGCGAA GGCCACTTGC	1380
ACTCTGGCTG CACCTCACTG GGCCAGAGCT GATCCTTGAG TGGCCAGGGC CTCTTCCTT	1440
25 CCTCATAGCA CAGGGGTGAG CCTTGACACAC CTAAGCCCCG CCCTCCACAT CCTTTGTT	1500
GTCACCTTCT GGAGCCCTCC TGGCACCCAC TTTTCCCCAC AGCTTGCGGA GGCCACTCAG	1560
GTCTCAGGTG TAACAGGTGT AACCATAACCC CACTCTCCCC CTTCCCGGG TTCAGGACCA	1620
CTTATTTTTT TATATAAGAC TTTTGAAATC TATTCGTGTA AATAAGAGTT GCTTGGCCAG	1680
AGCGGGAGCC CCTTGGGCTA TATTTATCTC CCAGGCATGC TGTGCTAGTC AACAAAAACT	1740
30 TTGTATGTTT ATTCCCTCAAG CGGGCGAGTC AGGTGTTGGA AATCC	1785

(2) INFORMATION FOR SEQ ID NO:2:

35 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1571 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

GGTCNNNNCT	ACAGAGGCCG	GGGCAGGGCCC	AGCCCATGGT	GCCCAGTGAA	TGCAACTCCC	60	
AGGGGCCCTC	NNCTGCGGGA	CGTTGGGGC	CACTGGCAGG	AACAAGCCTT	TTGCGACCTG	120	
ATGGAGCTGT	ATGAGACATC	CCCTATTT	TACCAAGGAGC	CCCACCTCTA	TGATGGGAA	180	
5	AACTACCTTC	CTGTCCACCT	TCAGGGCTTC	GAGCCCCCGG	GCTATGAGCG	GACTGAGCTC	240
AGCTTAAGCC	CGGAAGCCG	AGGGCCCTG	GAAGAAAAGG	GACTGGGAC	CCCTGAGCAT	300	
TGTCCAGGCC	AGTGCCTGCC	GTGGGCATGT	AAGGTGTGTA	AGAGGAAGTC	TGTGTCCGTG	360	
GACGGGAGGA	GGGCAGCCAC	ACTGAGGGAG	AAGCGCAGGC	TCAAGAAAGT	GAATGAGGCC	420	
TTCGAGGCC	TGAAGAGGAG	CACCTGCTC	AACCCCAACC	AGCGGCTGCC	TAAAGTGGAG	480	
10	ATCCTGCGCC	ATGCCATCCA	GTACATTGAG	CGCCTACAGG	CCTTGTCTAG	CTCCCTCAAC	540
CAGGAGGAGC	CGCATCTCCG	CTACAGAGGC	GGGGGCGGGC	CCAGCCCATG	GTGCCCAGTG	600	
AATGCAACTC	CCACAGCGCC	TCCTGCAGTC	CGGAGTGGGG	CAATGCACTG	GAGTTCCGTC	660	
CCAACCCAGG	AGATCATTG	CTCGCGGCTG	ACCCCTACAGA	CGCCACAAAT	CTGCACTCCC	720	
TTACGTCCAT	CGTGGACAGC	ATCACGGTGG	AGGATATGTC	TGTTGCCTTC	CCAGACGAAA	780	
15	CCATGCCCAA	CTGAGATTGT	CTGTCAAGCT	GGGTGTGCAT	GTGAGCCCC	AAGTTGGTGT	840
CAAAGCCAT	CACTCTGTA	GCAGGGGGCT	TTTAAGTGGG	GCTGTCTGA	TGTCCAGAAA	900	
ACAGCCCTGG	GCTGCCACAA	GCCAGACTCC	CCACTCCCCA	TTCACATAAG	GCTAACACCC	960	
AGCCCAGGGA	GGGAATTAG	CTGACTCCTT	AAAGCAGAGA	GCATCCTCTT	CTGAGGAGAG	1020	
AAAGATGCAG	TCCAGAGAGC	CCCCTGTTA	ATGCTCTCA	GTGGGGCAAA	CTCAGGAGCT	1080	
20	TCTTTTTGT	TTATCATATA	TGCCTCGAAT	TCCACCCCCC	ACCCCCAAAA	TGAAACCGTT	1140
TGAGAGACAT	GAGTGCCTG	ACCTGGACAA	GTGTGCACAT	CTGTTCTAGT	CTCTTCTGA	1200	
AGCCAGTGGC	TGGGCTGGGC	CTGCCCTGAG	TTGAGAGAGA	AGGGGGAGGA	GCTATCCGGT	1260	
TCCAAAGCCT	CTGGGGGCCA	AGCATTGCA	GTGGATCTTG	GGNNNNNTCC	AGTGTCTTGT	1320	
GTATTGTTA	TTGTTTTGTG	TGTTGTTGT	AAAGCTGCCG	TCTGCCAAGG	TCTCTGTGC	1380	
25	TGATGATACC	GGGAACAGGC	AGGCCAGGGG	GTGGGGCTC	TTGGGGTGAC	TTCTTTGTT	1440
AACTAAGCAT	TGTGTGGTTT	TGCCAATTTT	TTTCTTTG	TAATTCTTT	GCTAACTTAT	1500	
TTGGATTTCC	TTTTAAAAA	AATGAATAAA	GAATGGTTGC	TATCAGAAAA	AAAAAAA	1560	
AAAAAAAAAA	A					1571	

(2) INFORMATION FOR SEQ ID NO:3:

30 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1296 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

35 (ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GTCCATCAC	CAGTCAGAT	CAGTCAGAGG	CCAAGGAGGA	GAACATGATG	ATGGACCTT	60
-----------	-----------	------------	------------	------------	-----------	----

WO 95/12979

28

TTGAAACTGG CTCCATTTC TTCTACTTAG ATGGAGAAAA TGTGACTCTT CAGCCATTAG 120
 AAGTGGCAGA GGGCTCTCCT TTGTACCCAG GGAGTGTGG TACCTATCC CCTTGCCAGG 180
 ACCAAATGCC CCAGGAAGCC GGGAGCGACA GCAGTGGAGA GGAACACGTT CTGGCTCCCC 240
 CAGGCCCTCA GCCACCCAC TGCCAGGTC AGTGTCTGAT CTGGCTTGC AAGACTTGCA 300
 5 AGAGAAAATC TGCCCCACA GATGTCGGA AAGCAGCTAC CCTGCGCGAA AGGAGGAGGC 360
 TTAAGAAAAT CAACGAAGCC TTTGAGGCCT TGAAGCGTAG AACTGTGGCC AACCCCAACC 420
 AGAGGCTGCC CAAGGTGGAG ATTCTGAGAA GTGCCATCAA CTACATTGAG CGTCTGCAGG 480
 ACCTGCTGCA CCGGCTGGAT CAGCAAGAGA AAATGCAAGA GCTGGGGGTG GACCCCTACA 540
 GCTACAAACC CAAGCAAGAA ATTCTTGAGG GTGCCGGATT CCTGCGCACC TGCAGCCCGC 600
 10 AGTGGCCAG TGTTCGGAT CATTCCAGGG GCCTGGTGAT AACTGCTAAG GAAGGAGGAG 660
 CAAGCGTGA TGCTTCAGCC TCCAGCAGTC TTCAAGCGCT TTCTTCATC GTGGACAGTA 720
 TTTCCCTCAGA GGAACGCAA CTCCCCAGCG TGGAGGAGGT GGTGGAGAAG TAACTCAGTC 780
 AGCATTTGGA ACATTCTCG CTCAAGAGA AGAGCCCCCT TCCGGCTAAAT CATTAGATT 840
 AGGGCTCACA GACCCAGAA TTATGAAAG GCAAGAGACT TAGTGTAAA AAAGAAACCT 900
 15 CTCCCCACCT CAAGTAAAAA TCCCTCGCT TGGGGCTTTT ATTATAACTA TTATTGTATC 960
 TGAACCGCTA GTGGCTTAGC TCTAGAACCC TAATTTGTT TTAGTTGG TTGGTTTTTT 1020
 ATAACATATT AACTTTGCT ATGATCACGT GACCCCTTCC TGTCAAGTGC AAACGAAGTT 1080
 CATTCCCTGTC TAAATCAAAG TGGGAACGTT TAATCCTAAG AGTATTTAAAT GTACTTTGT 1140
 AAATAGTCTT AGTACTTCG TTTTATGTA AACCTAAAGG ACATATTTAAT AATGTGGAAT 1200
 20 TAAGCATTGT ATATAAAATG TGTGAGAGTC TGATATTGTA ATATTTAAAT ATTAATACGT 1260
 TTCTACACGT AAAAAAAA AAAAAAAA AAAAAA 1296

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 1432 base pairs
 25 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
 30 CCTCTCGCTG CCGTCCAGGT GCACCGCTG CCTCTCAGCA GGATGGACGT GATGGATGGC 60
 TGCCAGTTCT CACCTCTGA GTACTCTAC GACGGCTCT GCATACCGTC CCCCCAGGGGT 120
 GAATTTGGGG ACGAGTTGT GCGCGAGTG GCTGCCCTCG GAGCGCACAA AGCAGAGCTG 180
 CAGGGCTCAG ATGAGGACGA GCACGTGCGA GCGCTTACCG GCCACCCACCA GGCTGGTCAC 240
 TGCCTCATGT GGGCTGCAA AGCCTGCAAG AGGAAGTCCA CCACCATGGA TCGGGGAAG 300
 35 GCAGGCCACTA TGCGCGAGCG GAGGCCCTG AAGAAGGTCA ACCAGGCTT CGAAACCCCTC 360
 AAGAGGTGTA CCACGACCAA CCCCAACCG AGGCTGCCA AGGTGGAGAT CCTCAGGAAT 420
 GCCATCCGCT ACATCGAGAG CCTGCAAGAG TTGCTGAGAG ACCAGGTGGA GAACCTACTAT 480

	AGCCTGCCGG GACAGAGCTG CTCGGAGCCC ACCAGCCCCA CCTCCAAGTG CTCTGATGGC	540
	ATGCCCGAAT GTAACAGTCC TGTCTGGTCC AGAAAGAGCA GTACTTTGA CAGCATCTAC	600
	TGTCTGATG TATCAAATGT ATATGCCACA GATAAAAACCT CTTTATCCAG CTTGGATTGC	660
	TTATCCAACA TAGTGGACCG GATCACCTCC TCAGAGCAAC CTGGGTTGCC TCTCCAGGAT	720
5	CTGGCTTCTC TCTCTCCAGT TGCCAGCACC GATTACAGC CTCGAACCTCC AGGGGCTTCT	780
	AGTTCCAGGC TTATCTATCA TGTGCTATGA ACTAATTTTC TGGTCTATAT GACTTCTTCC	840
	AGGAGGGCCT AATACACAGG ACGAAGAAGG CTTCAAAAG TCCCAACCA AGACAACATG	900
	TACATAAAGA TTCTTTCA GTTGAAATT TGAAAGATT ACCTTGCCAC TTTATAAGAA	960
	AGTGTATTTA ACTAAAAAGT CATCATTGCA AATAATACCT TCTTCTTCTT TATTATTCTT	1020
10	TGCTTAGATA TTAATACATA GTTCCAGTAA TACTATTCTC GATAGGGGGC CATTGATTGA	1080
	GGGTAGCTTG TTCAATGCT TAACTTATAT ATACATATAT ATATATTATA AATATTGCTC	1140
	ATCAAAATGT CTCTGGTGT TAGAGCTTA TTTTTCTT TAAACATTA AAACAGCTGA	1200
	GAATCAGTTA AATGGAATT TAAATATATT TAACTATTTC TTTCTCTTT AATCCTTGT	1260
	TTATATTGTA TAAATAAAA ATATAATCT GCCTAATGTA TATATTTGA TCTTTCTTG	1320
15	TAAGAAATGT ATCTTTAAA TGTAAGCACA AAATAGTACT TTGTGGATCA TTTCAAGATA	1380
	TAAGAAATTG TGAAATTCC ACCATAAATA AAATTTTTA CTACAAGAAA AA	1432

WHAT IS CLAIMED IS:

1. A method of transducing proliferating cells to a novel phenotype, comprising administering to the cells an amount effective to transduce at least a portion of the cells of a composition comprising a nucleotide molecule including at least one sequence corresponding to a cell lineage commitment gene.

5

2. A method according to claim 1, wherein said cell lineage commitment gene is a muscle regulatory factor gene.

10

3. A method according to claim 2, wherein said muscle regulatory factor gene is selected from the group consisting of MyoD, myogenin, Myf-5 and MRF4.

4. A method for treating injured and traumatized muscle tissue, comprising administering to the tissue a composition comprising at least one nucleotide molecule including at least one sequence corresponding to a muscle regulatory factor gene.

15

5. A method according to claim 4, wherein said muscle regulatory factor gene is selected from the group consisting of MyoD, myogenin, Myf-5 and MRF4.

20

6. A composition for transducing proliferating cells to a novel phenotype, comprising a suitable carrier or adjuvant and at least one nucleotide molecule including at least one sequence corresponding to a cell lineage commitment gene.

7. A composition according to claim 6, wherein said cell lineage commitment gene is a muscle regulatory factor gene.

8. A composition according to claim 7, wherein said muscle regulatory factor gene is selected from the group consisting of MyoD, myogenin, Myf-5 and MRF4.

INTERNATIONAL SEARCH REPORT

International application N
PCT/US94/12912

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 43/04; A61K 31/70; C07H 17/00; C12N 15/00
US CL : 435/ 172.1, 172.3, 320.1; 514/44; 536/ 23.1, 23.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/ 172.1, 172.3, 320.1; 514/44; 536/ 23.1, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS, CA, BIOSIS, EMBASE, MEDLINE, DERWENT BIOTECHNOLOGY ABSTRACTS
search terms: MyoD, retrovirus, infarction, heart

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Cell, Volume 51, issued December 1987, R.L. Davis et al., "Expression of a Single Transfected cDNA Converts Fibroblasts to Myoblasts", pages 987-1000, see the entire document.	1-3, 6-8 ----- 4, 5
Y	Proceedings of the National Academy of Science, USA, Volume 88, issued May 1991, R.N. Kitsis et al., "Hormonal modulation of a gene injected into rat heart <i>in vivo</i> ", pages 4138-4142, see the entire document.	1-8
Y	Development, Volume 114, issued 1992, J.H. Miner et al., "Skeletal muscle phenotypes initiated by ectopic MyoD in transgenic mouse heart", pages 853-860, see the entire document.	1-8

 Further documents are listed in the continuation of Box C. See patent family annex.

•	Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•A*	document defining the general state of the art which is not considered to be of particular relevance	X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•E*	earlier document published on or after the international filing date	Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•L*	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)		document member of the same patent family
•O*	document referring to an oral disclosure, use, exhibition or other means		
•P*	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

08 DECEMBER 1994

Date of mailing of the international search report

JAN 24 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

BRUCE CAMPBELL

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/12912

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	Circulation, Volume 88, No. 4 part 2, issued 08 November 1993, H. Prentice et al., "Transformation of Cardiac Fibroblasts into the Skeletal Muscle Phenotype by Injection of a MyoD-Expressing Retrovirus into Ischemic Heart", page I-475, see the abstract.	1-8
Y	Circulation Research, Volume 72, issued 1993, R. von Harsdorf et al., "Gene Injection Into Canine Myocardium as a Useful Model for Studying Gene Expression in the Heart of Large Mammals", pages 688-695, see the entire document.	1-8
A	Science, Volume 261, issued 15 February 1991, H. Weintraub et al., "The myoD Gene Family: Nodal Point During Specification of the Muscle Cell Lineage", pages 761-766, see the entire document.	1-8
Y	Circulation, Volume 82, No. 6, issued December 1990, H. Lin et al., "Expression of Recombinant Genes in Myocardium <i>In Vivo</i> After Direct Injection of DNA", pages 2217-2221, see the entire document.	1-8

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)